Hansepran 50 Capsule contains Clofazimine 50 mg, an antimicrobial agent primarily used in the treatment of leprosy (Hansen’s disease). Clofazimine exhibits anti-inflammatory and bactericidal properties, effectively targeting Mycobacterium leprae, the causative organism of leprosy. The drug works by binding to the mycobacterial DNA, thereby inhibiting bacterial replication and growth. Hansepran 50 is typically administered as part of a multidrug therapy regimen to reduce the risk of resistance development and to enhance treatment efficacy. It is indicated for both multibacillary and paucibacillary forms of leprosy and may also be used off-label for certain mycobacterial infections. The recommended dosage and duration of therapy depend on the severity of the disease and patient response, and treatment should be supervised by a healthcare professional. Common adverse effects include skin discoloration, gastrointestinal disturbances, and dry skin, which are generally reversible upon discontinuation. Patients should be monitored regularly for signs of adverse reactions and therapeutic response. Hansepran 50 Capsule should be used cautiously in patients with a history of gastrointestinal disorders or hypersensitivity to clofazimine. It is contraindicated in individuals with known hypersensitivity to the drug or its components.